Free Trial
→ New Rule Hits in July — The Smart Money Already Moved (From American Alternative) (Ad)
NASDAQ:OPGN

OpGen 8/10/2023 Earnings Report

OpGen logo
$4.88 0.00 (0.00%)
As of 06/20/2025 03:51 PM Eastern
ProfileEarnings History

OpGen EPS Results

Actual EPS
-$9.30
Consensus EPS
-$7.10
Beat/Miss
Missed by -$2.20
One Year Ago EPS
-$26.00

OpGen Revenue Results

Actual Revenue
$0.74 million
Expected Revenue
$0.90 million
Beat/Miss
Missed by -$160.00 thousand
YoY Revenue Growth
N/A

OpGen Announcement Details

Quarter
Date
8/10/2023
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

OpGen's next earnings date is estimated for Monday, July 7, 2025, based on past reporting schedules.

Conference Call Resources

OpGen Earnings Headlines

OpGen Forms Joint Venture with European Bank
May 29, 2025 | tipranks.com
OpGen Delays 10-Q Filing Amid Operational Challenges
May 16, 2025 | tipranks.com
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
June 21, 2025 | American Alternative (Ad)
OpGen Inc ziet aanzienlijke aankoop van aandelen door AEI Capital Ltd
December 11, 2024 | nl.investing.com
OpGen Inc aandeelhouder AEI Capital Ltd verhoogt belang met aankoop van €1,9 biljoen
December 10, 2024 | nl.investing.com
OpGen Appoints New COO and Company Secretary
December 6, 2024 | tipranks.com
See More OpGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OpGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OpGen and other key companies, straight to your email.

About OpGen

OpGen (NASDAQ:OPGN), a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

View OpGen Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles